Login to Your Account

Pharma: Other News To Note

Friday, March 8, 2013
• Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen, Denmark, said that Abilify Maintena (ariprazole), an extended-release (once-monthly) injectable suspension for schizophrenia will become available on the U.S. market on March 18, following its approval by the FDA on Feb. 28.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription